Pharvaris Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Pharvaris de 28.4% y 65.1% por año respectivamente. Se prevé que el BPA crezca en un 33.6% al año. Se espera que la rentabilidad financiera sea de -39.2% en 3 años.

Información clave

28.4%

Tasa de crecimiento de los beneficios

33.6%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Pharmaceuticals	22.8%
Tasa de crecimiento de los ingresos	65.1%
Rentabilidad financiera futura	-39.2%
Cobertura de analistas	Low
Última actualización	16 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

No hay actualizaciones

Recent updates

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:PHVS - Estimaciones futuras de los analistas y datos financieros pasados (EUR Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2026	10	-164	-208	N/A	3
12/31/2025	N/A	-136	-190	N/A	3
12/31/2024	N/A	-115	-144	N/A	4
12/31/2023	N/A	-101	-93	-93	N/A
9/30/2023	N/A	-107	-90	-90	N/A
6/30/2023	N/A	-92	-81	-81	N/A
3/31/2023	N/A	-83	-75	-74	N/A
12/31/2022	N/A	-76	-67	-67	N/A
9/30/2022	N/A	-49	-59	-59	N/A
6/30/2022	N/A	-50	-54	-54	N/A
3/31/2022	N/A	-53	-52	-52	N/A
12/31/2021	N/A	-43	-45	-45	N/A
9/30/2021	N/A	-41	-41	-41	N/A
6/30/2021	N/A	-38	-38	-38	N/A
3/31/2021	N/A	-29	-29	-29	N/A
12/31/2020	N/A	-26	-22	-21	N/A
9/30/2020	N/A	-19	-16	-16	N/A
12/31/2019	N/A	-8	-7	-7	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que PHVS siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que PHVS siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que PHVS siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que PHVS no tenga ingresos el año que viene.

Ingresos de alto crecimiento: Se prevé que PHVS no tenga ingresos el año que viene.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: PHVS se prevé que no sea rentable en 3 años.

Pharvaris Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

Chief Business Officer notifies of intention to sell stock

New minor risk - Share price stability

Chief Early Development Officer notifies of intention to sell stock

Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer

Independent Vice Chairman notifies of intention to sell stock

Co-Founder notifies of intention to sell stock

Chief Medical Officer notifies of intention to sell stock

Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Pharvaris: Digging Deep For Sufficient Market Size

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-Demand Treatment of HAE At the GA²LEN UCARE Conference 2023

New major risk - Shareholder dilution

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris N.V. has completed a Follow-on Equity Offering in the amount of $299.98625 million.

Pharvaris Announces Positive Top-Line Phase 2 Data from the Chapter-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks

Co-Founder notifies of intention to sell stock

Pharvaris Appoints Stefan Abele as Chief Technical Operations Officer

New major risk - Revenue and earnings growth

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Chief Medical Officer notifies of intention to sell stock

New major risk - Share price stability

Co-Founder notifies of intention to sell stock

Pharvaris N.V. Announces Board Changes

Pharvaris Announces FDA Removal of Clinical Hold of Deucrictibant for the On-Demand Treatment of HAE

Pharvaris Announces Data of Deucrictibant for the On-Demand Treatment of HAE Attacks Presented at the EAACI Congress 2023

Pharvaris N.V., Annual General Meeting, Jun 23, 2023

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

Companies Like Pharvaris (NASDAQ:PHVS) Are In A Position To Invest In Growth

Pharvaris Announces Positive Top-line Phase 2 Data from RAPIDe-1 Study of PHVS416 for the On-Demand Treatment of HAE Attacks

Less than half of directors are independent

Pharvaris Presents Data Supporting HAE Drug Development Strategy At the 2022 HAEi Global Leadership Workshop

Pharvaris Announces the Promotion of Annick Deschoolmeester to Chief Human Resources Officer

We Think Pharvaris (NASDAQ:PHVS) Can Afford To Drive Business Growth

Pharvaris GAAP EPS of -€0.38

Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S

Pharvaris slips 19% after FDA clinical hold on hereditary angioedema candidate

Chief Medical Officer notifies of intention to sell stock

Pharvaris N.V., Annual General Meeting, Jun 29, 2022

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris N.V. Appoints Joan Schmidt as Chief Legal Officer

Less than half of directors are independent

High number of new and inexperienced directors

Pharvaris (NASDAQ:PHVS) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Pharvaris' (NASDAQ:PHVS) Cash Burn Rate

Pharvaris reports Q1 results

Independent Non-Executive Director has left the company

Pharvaris Doses First Patient in RAPIDe-1, a Phase 2 Study Evaluating PHVS416 for the On-Demand Treatment of HAE

Pharvaris Presents Pharmacodynamic Activity of Oral PHA121, Under Development for the Treatment of HAE

Pharvaris B.V. has completed an IPO in the amount of $165.41 million.

Previsiones de crecimiento de beneficios e ingresos

Previsiones de crecimiento futuro de los analistas

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

Descubre empresas en crecimiento